Search

Your search keyword '"Choi, Woong Gil"' showing total 3 results
Start Over Author "Choi, Woong Gil" Topic diabetes mellitus
3 results on '"Choi, Woong Gil"'

1. Effect of hemoglobin A1c change on 24-month clinical outcomes in patients with diabetes after acute myocardial infarction.

Author

Park S, Choi WG, Bae DH, Kim M, Lee JH, Kim S, Bae JW, Kim DW, Cho MC, Kim CJ, Chae SC, Jeong MH, and Hwang KK

Subjects
Humans, Male, Female, Middle Aged, Republic of Korea epidemiology, Aged, Time Factors, Risk Factors, Patient Readmission statistics & numerical data, Blood Glucose metabolism, Glycemic Control methods, Treatment Outcome, Glycated Hemoglobin metabolism, Myocardial Infarction blood, Registries, Diabetes Mellitus blood, Diabetes Mellitus epidemiology, Biomarkers blood
Abstract

Background: The average glycated hemoglobin (HbA1c) may not accurately reflect glycemic control status during the mid-term after acute myocardial infarction (AMI). We aimed to evaluate changes in HbA1c and their effect on mid-term clinical outcomes in patients with diabetes and AMI., Methods: We enrolled patients with diabetes ( n  = 967) who underwent HbA1c measurement in the Korean nationwide registry. These patients were categorized into three groups based on changes in HbA1c from index admission to the 1-year follow-up visit: a decrease in HbA1c > 1%, changes in HbA1c within 1%, and an increase in HbA1c > 1%. Clinical outcomes at 24 months were examined., Results: The baseline HbA1c levels were 8.55 ± 0.85, 7.00 ± 0.98 and 7.07 ± 1.05 ( P  = 0.001) and HbA1c levels after 1 year were 6.62 ± 0.73, 7.05 ± 0.98 and 9.26 ± 1.59 ( P  = 0.001) for patients with 3 groups, respectively. Patients with a 1% decrease in HbA1c had significantly lower incidence of major adverse cardiovascular events (MACE), cardiac death, and rehospitalization after 24 months than those with a 1% increase in HbA1c. However, in the Cox regression analysis, a >1% decrease in HbA1c change was not an independent factor for MACE, cardiac death, and rehospitalization., Conclusions: Our analysis indicates that an HbA1c decrease of >1% within the first 12 months was not an independent prognostic factor until the 24-month mark. Therefore, standard diabetic control is recommended for patients with diabetes and AMI for up to 2 years., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

2. Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients

Author

Kim, Yong Hoon, Her, Ae-Young, Rha, Seung-Woon, Choi, Byoung Geol, Choi, Se Yeon, Byun, Jae Kyeong, Kang, Dong Oh, Jang, Won Young, Kim, Woohyeun, Baek, Ju Yeol, Choi, Woong Gil, Kang, Tae Soo, Ahn, Jihun, Park, Sang-Ho, Park, Sung Hun, Hong, Ji Yeon, Park, Ji Young, Lee, Min-Ho, Choi, Cheol Ung, Park, Chang Gyu, and Seo, Hong Seog

Published
2020
Full Text
View/download PDF

3. Calcium channel blocker monotherapy versus combination with renin-angiotensin system inhibitors on the development of new-onset diabetes mellitus in hypertensive Korean patients

Author

Kim, Yong Hoon, Her, Ae-Young, Rha, Seung-Woon, Choi, Byoung Geol, Choi, Se Yeon, Byun, Jae Kyeong, Park, Yoonjee, Kang, Dong Oh, Jang, Won Young, Kim, Woohyeun, Choi, Woong Gil, Kang, Tae Soo, Ahn, Jihun, Park, Sang-Ho, Park, Ji Young, Lee, Min-Ho, Choi, Cheol Ung, Park, Chang Gyu, and Seo, Hong Seog

Subjects
Calcium channel blocker, Renin-angiotensin system inhibitors, Diabetes mellitus, Research Article
Abstract

Background In real practice, two or more antihypertensive drugs are needed to achieve target blood pressure. We investigated the comparative beneficial actions of combination therapy of renin-angiotensin system inhibitors (RASI), with calcium channel blockers (CCB) over CCB monotherapy on the development of new-onset diabetes mellitus (NODM) in Korean patients during four-year follow-up periods. Methods A total of 3208 consecutive hypertensive patients without a history of diabetes mellitus who had been prescribed CCB were retrospectively enrolled from January 2004 to December 2012. These patients were divided into the two groups according to the additional use of RASI (the RASI group, n = 1221 and the no RASI group, n = 1987). Primary endpoint was NODM, defined as a fasting blood glucose ≥ 126 mg/dL or hemoglobin A1c ≥ 6.5%. Secondary endpoint was major adverse cardiac events (MACE) defined as total death, myocardial infarction (MI) and percutaneous coronary intervention (PCI). Results After propensity score-matched (PSM) analysis, two propensity-matched groups (939 pairs, n = 1878, C-statistic = 0.743) were generated. The incidences of NODM (HR = 1.009, 95% CI: 0.700–1.452, P = 0.962), MACE (HR = 0.877, 95% CI: 0.544–1.413, P = 0.589), total death, MI, PCI were similar between the two groups after PSM during four years. Conclusions The use of RASI in addition to CCB showed comparable incidences of NODM and MACE compared to CCB monotherapy in non-diabetic hypertensive Korean patients during four-year follow-up period. However, large-scaled randomized controlled clinical trials will be required for a more definitive conclusion.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results